Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PAHC Stock Summary
Top 10 Correlated ETFs
PAHC
In the News
Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
Here's Why Investors Should Buy Phibro (PAHC) Stock Now
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
Is Phibro Animal Health (PAHC) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Animal Health Corporation to Participate in Barclays Global Healthcare Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Tuesday, March 12, 2024, at 4:35 PM ET at the Loews Miami Beach Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investo.
What Makes Phibro (PAHC) a New Buy Stock
Phibro (PAHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Animal Health Corporation (PAHC) Q2 2024 Earnings Call Transcript
Phibro Animal Health Corporation (PAHC) Q2 2024 Earnings Call Transcript
Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down
Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.
PAHC Financial details
PAHC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 20.5 | 19.79 | 20.59 | 23.26 | 24.14 | |
Net income per share | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | |
Operating cash flow per share | 1.17 | 1.47 | 1.19 | 0.78 | 0.33 | |
Free cash flow per share | 0.43 | 0.63 | 0.47 | -0.13 | -0.95 | |
Cash per share | 2.02 | 2.26 | 2.3 | 2.25 | 2.01 | |
Book value per share | 5.35 | 4.65 | 5.89 | 6.48 | 6.97 | |
Tangible book value per share | 3.49 | 1.6 | 3.05 | 3.59 | 4.3 | |
Share holders equity per share | 5.35 | 4.65 | 5.89 | 6.48 | 6.97 | |
Interest debt per share | 8.37 | 10.47 | 10.86 | 11.91 | 13.03 | |
Market cap | 1.28B | 1.06B | 1.17B | 774.84M | 554.9M | |
Enterprise value | 1.55B | 1.44B | 1.55B | 1.17B | 1.02B | |
P/E ratio | 23.35 | 31.67 | 21.49 | 15.76 | 17.02 | |
Price to sales ratio | 1.54 | 1.33 | 1.4 | 0.82 | 0.57 | |
POCF ratio | 27.08 | 17.91 | 24.2 | 24.48 | 41.69 | |
PFCF ratio | 73.93 | 42 | 61.56 | -143.62 | -14.42 | |
P/B Ratio | 5.91 | 5.65 | 4.9 | 2.95 | 1.96 | |
PTB ratio | 5.91 | 5.65 | 4.9 | 2.95 | 1.96 | |
EV to sales | 1.87 | 1.8 | 1.85 | 1.24 | 1.05 | |
Enterprise value over EBITDA | 18.54 | 20.77 | 20.63 | 14.82 | 9.44 | |
EV to operating cash flow | 32.78 | 24.21 | 31.99 | 37 | 76.9 | |
EV to free cash flow | 89.48 | 56.8 | 81.39 | -217.07 | -26.6 | |
Earnings yield | 0.04 | 0.03 | 0.05 | 0.06 | 0.06 | |
Free cash flow yield | 0.01 | 0.02 | 0.02 | -0.01 | -0.07 | |
Debt to equity | 1.51 | 2.18 | 1.79 | 1.79 | 1.81 | |
Debt to assets | 0.45 | 0.52 | 0.51 | 0.5 | 0.52 | |
Net debt to EBITDA | 3.22 | 5.41 | 5.03 | 5.02 | 4.32 | |
Current ratio | 3.02 | 2.87 | 3.04 | 2.97 | 3.33 | |
Interest coverage | 6.21 | 2.86 | 3.33 | 3.89 | 4 | |
Income quality | 0.86 | 1.77 | 0.89 | 0.64 | 0.41 | |
Dividend Yield | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | |
Payout ratio | 0.34 | 0.58 | 0.36 | 0.4 | 0.6 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0.1 | 0.16 | 0.14 | 0.13 | 0.11 | |
Capex to operating cash flow | -0.63 | -0.57 | -0.61 | -1.17 | -3.89 | |
Capex to revenue | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | |
Capex to depreciation | -1.08 | -1.05 | -0.92 | -1.13 | -1.52 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Graham number | 12.76 | 9.32 | 13.35 | 13.3 | 11.24 | |
ROIC | 0.1 | 0.04 | 0.05 | 0.04 | 0.05 | |
Return on tangible assets | 0.08 | 0.05 | 0.07 | 0.06 | 0.04 | |
Graham Net | -5.21 | -7.7 | -7.2 | -7.99 | -8.55 | |
Working capital | 311.94M | 294.6M | 334.79M | 375.4M | 409.72M | |
Tangible asset value | 141.19M | 64.53M | 123.57M | 145.36M | 174.25M | |
Net current asset value | -44.49M | -144.06M | -103.89M | -103.03M | -103.17M | |
Invested capital | 1.51 | 2.18 | 1.79 | 1.79 | 1.81 | |
Average receivables | 147.38M | 142.77M | 136.69M | 156.69M | 165.01M | |
Average payables | 66.34M | 69.64M | 67.23M | 81.98M | 84.72M | |
Average inventory | 188.25M | 197.49M | 206.49M | 237.74M | 268.36M | |
Days sales outstanding | 70.1 | 57.7 | 64.32 | 64.51 | 61.02 | |
Days payables outstanding | 47.42 | 44.38 | 44.4 | 53.12 | 39.66 | |
Days of inventory on hand | 128.48 | 132.07 | 140.49 | 144 | 149.07 | |
Receivables turnover | 5.21 | 6.33 | 5.68 | 5.66 | 5.98 | |
Payables turnover | 7.7 | 8.22 | 8.22 | 6.87 | 9.2 | |
Inventory turnover | 2.84 | 2.76 | 2.6 | 2.53 | 2.45 | |
ROE | 0.25 | 0.18 | 0.23 | 0.19 | 0.12 | |
Capex per share | -0.74 | -0.84 | -0.72 | -0.91 | -1.28 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 6.04 | 6.07 | 6.3 | 5.77 | 6.17 | |
Net income per share | 0.18 | 0.25 | 0.28 | -0.2 | 0.03 | |
Operating cash flow per share | -0.06 | 0.15 | 0.5 | 0.4 | 0.78 | |
Free cash flow per share | -0.3 | -0.04 | 0.23 | 0.22 | 0.51 | |
Cash per share | 1.94 | 1.91 | 2.01 | 2.27 | 2.28 | |
Book value per share | 6.63 | 6.72 | 6.98 | 6.81 | 6.69 | |
Tangible book value per share | 3.85 | 4 | 4.3 | 4.18 | 4.08 | |
Share holders equity per share | 6.63 | 6.72 | 6.98 | 6.81 | 6.69 | |
Interest debt per share | 12.74 | 12.88 | 12.72 | 13.05 | 12.8 | |
Market cap | 543.16M | 620.46M | 554.85M | 511.76M | 469.04M | |
Enterprise value | 986.48M | 1.1B | 1.02B | 986.95M | 949.16M | |
P/E ratio | 18.83 | 15.45 | 12.06 | -15.99 | 92.04 | |
Price to sales ratio | 2.22 | 2.53 | 2.18 | 2.21 | 1.88 | |
POCF ratio | -218.22 | 99.13 | 27.42 | 31.59 | 14.86 | |
PFCF ratio | -44.13 | -376.26 | 59.36 | 58.67 | 22.77 | |
P/B Ratio | 2.02 | 2.28 | 1.96 | 1.87 | 1.73 | |
PTB ratio | 2.02 | 2.28 | 1.96 | 1.87 | 1.73 | |
EV to sales | 4.03 | 4.48 | 4.01 | 4.27 | 3.8 | |
Enterprise value over EBITDA | 39.6 | 59.19 | 30.95 | -1.41K | 37.42 | |
EV to operating cash flow | -396.34 | 175.9 | 50.57 | 60.93 | 30.08 | |
EV to free cash flow | -80.15 | -667.64 | 109.5 | 113.14 | 46.08 | |
Earnings yield | 0.01 | 0.02 | 0.02 | -0.02 | 0 | |
Free cash flow yield | -0.02 | 0 | 0.02 | 0.02 | 0.04 | |
Debt to equity | 1.91 | 1.9 | 1.81 | 1.9 | 1.89 | |
Debt to assets | 0.53 | 0.54 | 0.52 | 0.54 | 0.53 | |
Net debt to EBITDA | 17.8 | 25.83 | 14.17 | -678.84 | 18.93 | |
Current ratio | 3.47 | 3.54 | 3.33 | 3.39 | 3.12 | |
Interest coverage | 3.56 | 2.59 | 4.54 | -0.15 | 2.9 | |
Income quality | -0.35 | 0.62 | 1.76 | -2.02 | 24.77 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.67 | 0.48 | 0.42 | -0.61 | 3.82 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0.1 | 0 | 0 | |
Intangibles to total assets | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | |
Capex to operating cash flow | 3.94 | -1.26 | -0.54 | -0.46 | -0.35 | |
Capex to revenue | -0.04 | -0.03 | -0.04 | -0.03 | -0.04 | |
Capex to depreciation | -1.15 | -0.93 | -1.27 | -0.84 | -1.23 | |
Stock based compensation to revenue | 0 | 0 | -0.02 | 0 | 0 | |
Graham number | 5.15 | 6.12 | 6.68 | 5.53 | 2.18 | |
ROIC | 0.01 | 0.01 | 0.02 | 0 | 0.01 | |
Return on tangible assets | 0.01 | 0.01 | 0.01 | -0.01 | 0 | |
Graham Net | -8.81 | -8.76 | -8.55 | -8.7 | -8.72 | |
Working capital | 414.12M | 420.18M | 409.72M | 412.07M | 398.85M | |
Tangible asset value | 156.08M | 162.18M | 174.25M | 167.63M | 165.16M | |
Net current asset value | -111.77M | -107.62M | -103.17M | -107.03M | -115.32M | |
Invested capital | 1.91 | 1.9 | 1.81 | 1.9 | 1.89 | |
Average receivables | 147.28M | 152.29M | 158.11M | 156.35M | 149.93M | |
Average payables | 84.43M | 78.13M | 74.81M | 75.53M | 81.81M | |
Average inventory | 284.91M | 290.91M | 285.2M | 278.36M | 282.92M | |
Days sales outstanding | 55.85 | 55.95 | 57.69 | 58.07 | 54.24 | |
Days payables outstanding | 43.31 | 40.09 | 37.26 | 42.48 | 45.39 | |
Days of inventory on hand | 155.5 | 154.94 | 140.04 | 153.57 | 150.6 | |
Receivables turnover | 1.61 | 1.61 | 1.56 | 1.55 | 1.66 | |
Payables turnover | 2.08 | 2.25 | 2.42 | 2.12 | 1.98 | |
Inventory turnover | 0.58 | 0.58 | 0.64 | 0.59 | 0.6 | |
ROE | 0.03 | 0.04 | 0.04 | -0.03 | 0 | |
Capex per share | -0.24 | -0.2 | -0.27 | -0.19 | -0.27 |
PAHC Frequently Asked Questions
What is Phibro Animal Health Corporation stock symbol ?
Phibro Animal Health Corporation is a US stock , located in Teaneck of Nj and trading under the symbol PAHC
Is Phibro Animal Health Corporation buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $18.67. The lowest prediction is $17 and the highest is $21
What is PAHC stock prediction ?
What is Phibro Animal Health Corporation stock quote today ?
Phibro Animal Health Corporation stock price is $13.06 today.
Is Phibro Animal Health Corporation stock public?
Yes, Phibro Animal Health Corporation is a publicly traded company.